awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34380368-76EF4A92-ACDC-440C-87C7-2182C88A0F0D
Q34380368-76EF4A92-ACDC-440C-87C7-2182C88A0F0D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34380368-76EF4A92-ACDC-440C-87C7-2182C88A0F0D
Development of synthetic lethality anticancer therapeutics.
P2860
Q34380368-76EF4A92-ACDC-440C-87C7-2182C88A0F0D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34380368-76EF4A92-ACDC-440C-87C7-2182C88A0F0D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d21b672f7d9aa4513a9bafd5edd46f2ddf42bb8b
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer